Company Overview
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
Recent News
GT Biopharma Reports Second Quarter 2023 Financial Results
Stock Overview
Symbol
GTBP
Exchange
Nasdaq
Market Cap
10.01m
Last Price
$0.2463
52-Week Range
$0.1797 - $2.30
09/22/2023 04:00 PM EDT